Vera Therapeutics Inc (VERA) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Vera Therapeutics Inc   (NASDAQ: VERA)


Vera Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Vera Therapeutics Inc's ROI in the second quarter of 2026?
Vera Therapeutics Inc recorded a cumulative net loss of $-402 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -72.61%.

Within the Healthcare sector 133 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2225 to 3762.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 5.46 % 17.38 % 30.5 % 74.98 % 92.99 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 485 577 679 474 543
Return On Investment (TTM) -72.61 % -64.95 % -52.45 % -45.12 % -41.59 %
VERA's Overall Ranking # 3762 # 2225 # 2658 # 3435 # 3269
Seq. Investment Change TTM -2.56 % -0.56 % 2.31 % 6.38 % 8.47 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -402 -369 -300 -252 -218

VERA Company Profile >> Back to VERA Roi Comparisons >> See Annual VERA Return On Investment



Return On Investment VERA's Ranking
Within: No.
Industry # 44
Sector # 134
Overall # 3762

Return On Investment Statistics
High Average Low
-34.63 %
-51.26 %
-73.53 %
(Dec 31 2024)   (Mar 31 2023)



  News about Vera Therapeutics Inc Return on Investment ROI

Vera Therapeutics Bolsters Leadership with Industry Veterans for Transformative Drug Program Development

January 8, 2024

Vera Therapeutics Strengthens Leadership Team with Industry Veterans to Drive Drug Program Development
Brisbane, Calif. - In a significant move to further advance its drug programs, late clinical-stage biotechnology company Vera Therapeutics, Inc. (Nasdaq: VERA) has announced the appointment of two industry veterans to its leadership team. Robert Brenner, M.D., has been appointed as Chief Medical Officer, while William D. Turner will take on the role of Chief Development Officer. These appointments come at a crucial time for Vera Therapeutics as it progresses its late-stage product candidate, atacicept, through a Phase 3 clinical trial for IgA nephropathy (IgAN), an autoimmune disease.
The appointment of Robert M. Brenner, M.D., as Chief Medical Officer marks a transition from the previous Chief Medical Officer, Dr. Celia Lin, M.D. Dr. Brenner brings a wealth of experience to his new role, having spent several years in the industry and having contributed significantly to the development of various drug programs. His extensive knowledge, expertise, and strategic mindset will be instrumental in advancing Vera Therapeutics drug portfolio, particularly atacicept, in its fight against serious immunologic diseases.





Financial Statements
Vera Therapeutics Inc's II. Quarter Investments $ 485 Millions VERA's Balance sheet
Vera Therapeutics Inc's II. Quarter Income $ -109 Millions Quarterly VERA's Income Statement
VERA's Income by Division See VERA's Income by Division


VERA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 679 628 153 106 76
Y / Y Investment Growth 8.21 % 309.7 % 44.79 % 38.98 % -
Net Income in Millions -300 -152 -96 -89 -33
Y / Y Net Income Growth - - - - -
Annual Return On Investment -44.1 % -24.23 % -62.64 % -84.15 % -42.82 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
VERA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for VERA's Competitors
Subscribers only: Roi for Vera Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for VERA's Customers

Other Ratios
VERA's Roa VERA's Inventory Turnover Ratio VERA's Growth Rates VERA's Dividend Statistics
VERA's Profitability Ratios VERA's Asset Turnover Ratio VERA's Dividend Growth
VERA's Roe VERA's Valuation Ratios VERA's Financial Strength Ratios VERA's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:39:49+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.